dwb2023/gtopdb-target-family-interaction-detail huggingface dataset:
Target family: Mitochondrial-associated proteins (type: other_protein)
Target: Translocator protein

Ligand: PK 11195 (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 8.149999618530273 pKi
Reference (Journal): Synthesis of 6-[¹⁸F]fluoro-PBR28, a novel radiotracer for imaging the TSPO 18 kDa with PET.
Published in: Bioorg Med Chem Lett

Ligand: BAY-069 (Synthetic organic)
Interaction type: None
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.130000114440918 pKi
Reference (Webpage): Data for DCP probe BAY-069

Ligand: emapunil (Synthetic organic)
Interaction type: Agonist
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 7.519999980926514 pKi
Reference (Journal): Variation in binding affinity of the novel anxiolytic XBD173 for the 18 kDa translocator protein in human brain.
Published in: Synapse

Ligand: emapunil (Synthetic organic)
Interaction type: Agonist
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 8.619999885559082 pKi
Reference (Journal): Variation in binding affinity of the novel anxiolytic XBD173 for the 18 kDa translocator protein in human brain.
Published in: Synapse

Ligand: emapunil (Synthetic organic)
Interaction type: Agonist
Action: Agonist
Ligand approved: no
Primary target: yes
Median affinity: 9.699999809265137 pKi
Reference (Journal): [18F]FEAC and [18F]FEDAC: Two novel positron emission tomography ligands for peripheral-type benzodiazepine receptor in the brain.
Published in: Bioorg Med Chem Lett
Target family: Mitochondrial di- and tri-carboxylic acid transporter subfamily (type: transporter)
Target: Mitochondrial citrate transporter

Ligand: 1,2,3-benzenetricarboxylic acid (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity:  -

Ligand: CTPI-2 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.460000038146973 pKd
Reference (Journal): The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer.
Published in: Cell Death Differ
Target family: Mitochondrial nucleotide transporter subfamily (type: transporter)
Target: Mitochondrial adenine nucleotide translocator 1

Ligand: carboxyatractyloside (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity:  -

Ligand: bongkrek acid (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity:  -
Target family: Mitofusin proteins (type: enzyme)
Target: mitofusin 2

Ligand: compound 13B [PMID: 32506913] (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity: 8.109999656677246 pEC50
Reference (Journal): Discovery of 6-Phenylhexanamide Derivatives as Potent Stereoselective Mitofusin Activators for the Treatment of Mitochondrial Diseases.
Published in: J Med Chem
Target family: MKN subfamily (type: enzyme)
Target: MAPK interacting serine/threonine kinase 1

Ligand: dorsomorphin (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.960000038146973 pIC50
Reference (Journal): The rational design of a novel potent analogue of the 5'-AMP-activated protein kinase inhibitor compound C with improved selectivity and cellular activity.
Published in: Bioorg Med Chem Lett

Ligand: MNK1 inhibitor (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 6.059999942779541 pIC50
Reference (Journal): Discovery of mitogen-activated protein kinase-interacting kinase 1 inhibitors by a comprehensive fragment-oriented virtual screening approach.
Published in: J Med Chem

Ligand: tinodasertib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.190000057220459 pIC50
Reference (Journal): Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia.
Published in: J Med Chem

Ligand: tomivosertib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.619999885559082 pIC50
Reference (Journal): Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition.
Published in: J Med Chem

Ligand: compound 20j [PMID: 38564512] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.359999656677246 pIC50
Reference (Journal): Development of an Imidazopyridazine-Based MNK1/2 Inhibitor for the Treatment of Lymphoma.
Published in: J Med Chem
Target family: MKN subfamily (type: enzyme)
Target: MAPK interacting serine/threonine kinase 2

Ligand: MELK-TI (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.119999885559082 pIC50
Reference (Journal): Fragment-based discovery of type I inhibitors of maternal embryonic leucine zipper kinase.
Published in: ACS Med Chem Lett

Ligand: MNK1 inhibitor (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.800000190734863 pIC50
Reference (Journal): Discovery of mitogen-activated protein kinase-interacting kinase 1 inhibitors by a comprehensive fragment-oriented virtual screening approach.
Published in: J Med Chem

Ligand: tinodasertib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.070000171661377 pIC50
Reference (Journal): Optimization of Selective Mitogen-Activated Protein Kinase Interacting Kinases 1 and 2 Inhibitors for the Treatment of Blast Crisis Leukemia.
Published in: J Med Chem

Ligand: tomivosertib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 9 pIC50
Reference (Journal): Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition.
Published in: J Med Chem

Ligand: compound 20j [PMID: 38564512] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.399999618530273 pIC50
Reference (Journal): Development of an Imidazopyridazine-Based MNK1/2 Inhibitor for the Treatment of Lymphoma.
Published in: J Med Chem
Target family: MLK subfamily (type: enzyme)
Target: ZAK sterile alpha motif and leucine zipper containing kinase AZK

Ligand: ZAK inhibitor 6p (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.399999618530273 pIC50
Reference (Journal): Design, Synthesis, and Structure-Activity Relationships of 1,2,3-Triazole Benzenesulfonamides as New Selective Leucine-Zipper and Sterile-α Motif Kinase (ZAK) Inhibitors.
Published in: J Med Chem

Ligand: ZAK inhibitor 6p (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.100000381469727 pKd
Reference (Journal): Design, Synthesis, and Structure-Activity Relationships of 1,2,3-Triazole Benzenesulfonamides as New Selective Leucine-Zipper and Sterile-α Motif Kinase (ZAK) Inhibitors.
Published in: J Med Chem

Ligand: KC-130 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.940000057220459 pIC50
Reference (Journal): Rational Design of Covalent Kinase Inhibitors by an Integrated Computational Workflow (Kin-Cov).
Published in: J Med Chem

Ligand: compound 15b [PMID: 16539403] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.150000095367432 pIC50
Reference (Journal): Dihydropyrrolopyrazole transforming growth factor-beta type I receptor kinase domain inhibitors: a novel benzimidazole series with selectivity versus transforming growth factor-beta type II receptor kinase and mixed lineage kinase-7.
Published in: J Med Chem
Target family: MLK subfamily (type: enzyme)
Target: mitogen-activated protein kinase kinase kinase 9

Ligand: URMC-099 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.71999979019165 pIC50
Reference (Journal): Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.
Published in: J Med Chem

Ligand: P505-15 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.059999942779541 pIC50
Reference (Journal): Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
Published in: J Pharmacol Exp Ther

Ligand: GNE-3511 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.170000076293945 pIC50
Reference (Journal): Discovery of dual leucine zipper kinase (DLK, MAP3K12) inhibitors with activity in neurodegeneration models.
Published in: J Med Chem

Ligand: compound 8e [PMID: 24432909] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.420000076293945 pIC50
Reference (Journal): Dual Leucine Zipper Kinase Inhibitors for the Treatment of Neurodegeneration.
Published in: J Med Chem

Ligand: cerdulatinib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.300000190734863 pIC50
Reference (Journal): The novel kinase inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-cell cancer.
Published in: J Pharmacol Exp Ther

Ligand: CEP-1347 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity:  pIC50
Reference (Journal): Dual Leucine Zipper Kinase Inhibitors for the Treatment of Neurodegeneration.
Published in: J Med Chem

Ligand: CEP-1347 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity:  pIC50
Reference (Journal): Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.
Published in: J Med Chem

Ligand: CEP-1347 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity:  pIC50
Reference (Journal): Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family.
Published in: J Biol Chem

Ligand: apitolisib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.630000114440918 pIC50
Reference (Journal): Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer.
Published in: J Med Chem
Target family: MLK subfamily (type: enzyme)
Target: mitogen-activated protein kinase kinase kinase 11

Ligand: URMC-099 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.849999904632568 pIC50
Reference (Journal): Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.
Published in: J Med Chem

Ligand: Sanofi-14h (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.079999923706055 pIC50
Reference (Journal): The hVps34-SGK3 pathway alleviates sustained PI3K/Akt inhibition by stimulating mTORC1 and tumour&#xa0;growth.
Published in: EMBO J

Ligand: compound 8 [PMID: 24044867] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.520000457763672 pIC50
Reference (Journal): Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.
Published in: J Med Chem

Ligand: CEP-1347 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family.
Published in: J Biol Chem

Ligand: CEP-1347 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.
Published in: J Med Chem
Target family: MLK subfamily (type: enzyme)
Target: mitogen-activated protein kinase kinase kinase 10

Ligand: URMC-099 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.380000114440918 pIC50
Reference (Journal): Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.
Published in: J Med Chem

Ligand: CEP-1347 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family.
Published in: J Biol Chem

Ligand: CEP-1347 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.
Published in: J Med Chem
Target family: Mono-ADP-ribosylating PARPs (type: enzyme)
Target: poly(ADP-ribose) polymerase family member 10

Ligand: compound 8a [PMID: 35500474] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.849999904632568 pIC50
Reference (Journal): Potent 2,3-dihydrophthalazine-1,4-dione derivatives as dual inhibitors for mono-ADP-ribosyltransferases PARP10 and PARP15.
Published in: Eur J Med Chem

Ligand: compound 32 [PMID: 30006177] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.639999866485596 pIC50
Reference (Journal): 4-(Phenoxy) and 4-(benzyloxy)benzamides as potent and selective inhibitors of mono-ADP-ribosyltransferase PARP10/ARTD10.
Published in: Eur J Med Chem
Target family: Mono-ADP-ribosylating PARPs (type: enzyme)
Target: poly (ADP-ribose) polymerase 3

Ligand: olaparib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: EMA & FDA (2014)
Primary target: no
Median affinity: 8.239999771118164 pKd
Reference (Journal): Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-<i>N</i>-methylpyridine-2-carboxamide (AZD5305): A PARP1-DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs.
Published in: J Med Chem
Target family: Mono-ADP-ribosylating PARPs (type: enzyme)
Target: poly(ADP-ribose) polymerase family member 11

Ligand: ITK7 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.849999904632568 pIC50
Reference (Journal): A Potent and Selective PARP11 Inhibitor Suggests Coupling between Cellular Localization and Catalytic Activity.
Published in: Cell Chem Biol
Target family: Mono-ADP-ribosylating PARPs (type: enzyme)
Target: poly(ADP-ribose) polymerase family member 14

Ligand: RBN012759 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.520000457763672 pIC50
Reference (Journal): A potent and selective PARP14 inhibitor decreases protumor macrophage gene expression and elicits inflammatory responses in tumor explants.
Published in: Cell Chem Biol
Target family: Mono-ADP-ribosylating PARPs (type: enzyme)
Target: poly(ADP-ribose) polymerase family member 15

Ligand: A101-(CONH2)-B322 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.699999809265137 pIC50
Reference (Journal): A Focused DNA-Encoded Chemical Library for the Discovery of Inhibitors of NAD<sup>+</sup>-Dependent Enzymes.
Published in: J Am Chem Soc
Target family: Mono-ADP-ribosylating PARPs (type: enzyme)
Target: TCDD inducible poly(ADP-ribose) polymerase

Ligand: atamparib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.65999984741211 pKd
Reference (Journal): Medicinal Chemistry Perspective on Targeting Mono-ADP-Ribosylating PARPs with Small Molecules.
Published in: J Med Chem

Ligand: (S)-XY-05 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.350000381469727 pIC50
Reference (Journal): Discovery of Highly Selective PARP7 Inhibitors with a Novel Scaffold for Cancer Immunotherapy.
Published in: J Med Chem
Target family: Mono-ADP-ribosylating PARPs (type: enzyme)
Target: poly (ADP-ribose) polymerase 3

Ligand: KU0058948 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.150000095367432 pKd
Reference (Journal): Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3.
Published in: J Med Chem

Ligand: ME0328 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 6.050000190734863 pIC50
Reference (Journal): Chemical probes to study ADP-ribosylation: synthesis and biochemical evaluation of inhibitors of the human ADP-ribosyltransferase ARTD3/PARP3.
Published in: J Med Chem
Target family: Mono-ADP-ribosylating PARPs (type: enzyme)
Target: poly(ADP-ribose) polymerase family member 15

Ligand: compound 8a [PMID: 35500474] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.400000095367432 pIC50
Reference (Journal): Potent 2,3-dihydrophthalazine-1,4-dione derivatives as dual inhibitors for mono-ADP-ribosyltransferases PARP10 and PARP15.
Published in: Eur J Med Chem
Target family: Mono-ADP-ribosylating PARPs (type: enzyme)
Target: poly(ADP-ribose) polymerase family member 10

Ligand: OUL35 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.480000019073486 pIC50
Reference (Journal): 4-(Phenoxy) and 4-(benzyloxy)benzamides as potent and selective inhibitors of mono-ADP-ribosyltransferase PARP10/ARTD10.
Published in: Eur J Med Chem
Target family: Mono-ADP-ribosylating PARPs (type: enzyme)
Target: TCDD inducible poly(ADP-ribose) polymerase

Ligand: atamparib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.520000457763672 pIC50
Reference (Journal): Potent 2,3-dihydrophthalazine-1,4-dione derivatives as dual inhibitors for mono-ADP-ribosyltransferases PARP10 and PARP15.
Published in: Eur J Med Chem
Target family: MSK subfamily (type: enzyme)
Target: ribosomal protein S6 kinase A4

Ligand: compound 23 [PMID: 35816678] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.070000171661377 pIC50
Reference (Journal): Identification of a Potent, Selective, and Brain-Penetrant Rho Kinase Inhibitor and its Activity in a Mouse Model of Huntington's Disease.
Published in: J Med Chem

Ligand: compound 8 [PMID: 17480064] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.519999980926514 pIC50
Reference (Journal): Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2).
Published in: J Med Chem
Target family: MSK subfamily (type: enzyme)
Target: ribosomal protein S6 kinase A5

Ligand: compound 23 [PMID: 35816678] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.840000152587891 pIC50
Reference (Journal): Identification of a Potent, Selective, and Brain-Penetrant Rho Kinase Inhibitor and its Activity in a Mouse Model of Huntington's Disease.
Published in: J Med Chem

Ligand: compound 24 [PMID: 15955699] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.850000381469727 pIC50
Reference (Journal): (1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: further optimisation as highly potent and selective MSK-1-inhibitors.
Published in: Bioorg Med Chem Lett

Ligand: SB-747651A (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 9.300000190734863 pIC50
Reference (Journal): (1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: further optimisation as highly potent and selective MSK-1-inhibitors.
Published in: Bioorg Med Chem Lett
Target family: MSN subfamily (type: enzyme)
Target: mitogen-activated protein kinase kinase kinase kinase 4

Ligand: PF06260933 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.430000305175781 pIC50
Reference (Journal): Discovery of an in Vivo Tool to Establish Proof-of-Concept for MAP4K4-Based Antidiabetic Treatment.
Published in: ACS Med Chem Lett
Target family: MSN subfamily (type: enzyme)
Target: misshapen like kinase 1

Ligand: pexmetinib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.590000152587891 pIC50
Reference (Journal): Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Published in: Cancer Res

Ligand: PF-03715455 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.220000267028809 pIC50
Reference (Journal): Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease.
Published in: J Med Chem

Ligand: PF06260933 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.100000381469727 pIC50
Reference (Journal): Discovery of an in Vivo Tool to Establish Proof-of-Concept for MAP4K4-Based Antidiabetic Treatment.
Published in: ACS Med Chem Lett